Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  International Journal of Oncology

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/IJO_00000772PMID 20878068
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A tumor vaccine containing anti‐CD3 and anti‐CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes

  2006cited by this paper
• T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.

  2005cited by this paper
• CD3 x CD28 cross-interacting bispecific antibodies improve tumor cell dependent T-cell activation.

  2005cited by this paper
• A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.

  2005cited by this paper
• T cell receptor (TCR) clustering in the immunological synapse integrates TCR and costimulatory signaling in selected T cells.

  2005cited by this paper
• Screening for the expression of soluble recombinant protein in Escherichia coli.

  2005cited by this paper
• Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory

  2005cited by this paper
• CD28 Signals in the Immature Immunological Synapse 1

  2004cited by this paper
• A revival of bispecific antibodies.

  2004cited by this paper
• High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules.

  2004cited by this paper
• T cells take aim at cancer

  2002cited by this paper
• Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis.

  2002cited by this paper
• Therapeutic Effects of Tumor Reactive CD4+ Cells Generated From Tumor-Primed Lymph Nodes Using Anti-CD3/Anti-CD28 Monoclonal Antibodies

  2002cited by this paper
• Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs.

  2001cited by this paper
• Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells

  2000cited by this paper
• Antigen-processing machinery breakdown and tumor growth.

  2000cited by this paper
• Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease

  2000cited by this paper
• The diversity of T‐cell co‐stimulation in the induction of antitumor immunity

  1999cited by this paper
• The makings of a tumor rejection antigen.

  1999cited by this paper
• Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.

  1999cited by this paper
• Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

  1999cited by this paper
• HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story.

  1999cited by this paper
• Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28‐mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC‐independent cytotoxicity

  1997cited by this paper
• Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.

  1997cited by this paper
• The Th1/Th2 paradigm.

  1997cited by this paper
• Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells.

  1997cited by this paper
• Viral hemagglutinin augments peptide‐specific cytotoxic T cell responses

  1993cited by this paper
• Immunity and metastasis: in situ activation of protective T cells by virus modified cancer vaccines.

  1992cited by this paper
• Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation.

  1992cited by this paper
• Generation of mammalian cells expressing stably measles virus proteins via bicistronic RNA.

  1991cited by this paper
• Hybrid antibodies can target sites for attack by T cells

  1985cited by this paper
• [Carcinoembryonic antigen (CEA)].

  1977cited by this paper

• Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy.

  2021cites this paper
• Antitumor effect of the Newcastle disease viral hemagglutinin–neuraminidase gene is expressed through an oncolytic adenovirus effect in osteosarcoma cells

  2018cites this paper
• Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance

  2015influential citation
• Multimodal Cancer Therapy Involving Oncolytic Newcastle Disease Virus, Autologous Immune Cells, and Bi-Specific Antibodies

  2014influential citation
• Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity.

  2011cites this paper
• Designing a point-of-care detection assay for tuberculosis

  2011cites this paper